<DOC>
	<DOC>NCT03017690</DOC>
	<brief_summary>An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.</brief_summary>
	<brief_title>Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Men and women must be 18 years of age or older A current diagnosis of advanced, unresectable GEPNET Provided written informed consent to participate in the study Currently receiving lanreotide or octreotide LAR and has received at least one prior injection of current somatostatin analogues (SSA). Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitate more than 1 injection on the same day Scheduled to receive any other treatment in the infusion center/room on the same day and as part of the same appointment Known hypersensitivity to somatostatin analogues</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>